A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)

VEXAS syndrome is a recently discovered inflammatory condition. It happens because of a change in a gene within blood cells, leading the body's immune system to attack healthy tissues. People with VEXAS often face severe, recurring symptoms, including extreme tiredness, painful joints, skin rashes, lung problems, and low blood counts.

At the moment, the main treatment is high-dose steroid medication. Although steroids help keep inflammation under control, they do not cure the condition. Taking them over months or years can also cause serious health issues, such as weakened bones, weight gain, and higher infection risks. Doctors urgently need new treatments that target the disease directly so patients can rely less on steroids.

The SIVEX trial is investigating a new drug called SIR9900. Researchers want to see how well it works and check for any unwanted side effects. They will track whether it calms inflammation markers in the blood (such as CRP and ferritin) and helps the body make healthier blood cells. Most importantly, they want to see if it gives people more days free from painful flare-ups while cutting down their steroid use.

To make sure the results are fair and accurate, this is a double-blind trial. This means half the participants will receive SIR9900 and half will receive a dummy pill (placebo). Neither you nor your study doctors will know which one you are taking during the trial, but you will be monitored very closely throughout.